Table 4. Number of Research Projects Included Under Each Cross-Cutting Theme and WHO Priority Area (known funding amounts indicated in brackets).
WHO Priority Area | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Theme | Number of
Projects |
Virus:
natural history... |
Animal and
environmental research... |
Epidemiological
studies |
Clinical
characterization and management |
Infection
prevention and control... |
Candidate
therapeutics R&D |
Candidate
vaccines R&D |
Ethics
considerations for research |
Social
sciences in the outbreak response |
N/A |
Indirect Health Impacts ($356.1m) | 27 | 0 | 77 | 243 | 119 | 12 | 2 | 37 | 1885 | 78 | |
Innovation ($286.4m) | 120 | 0 | 46 | 268 | 478 | 37 | 28 | 6 | 540 | 267 | |
Modelling ($235.1m) | 182 | 18 | 524 | 109 | 121 | 72 | 41 | 11 | 197 | 24 | |
Repurposed ($429.0m) | 180 | 6 | 79 | 210 | 69 | 173 | 38 | 6 | 298 | 52 | |
Cohorts ($398.0m) | 106 | 1 | 95 | 162 | 22 | 21 | 22 | 4 | 136 | 17 | |
Capacity Strengthening ($280.5m) | 61 | 3 | 40 | 36 | 34 | 23 | 13 | 14 | 178 | 29 | |
Long COVID ($292.1m) | 36 | 1 | 35 | 217 | 2 | 18 | 7 | 0 | 30 | 3 | |
Gender ($42.7m) | 6 | 0 | 10 | 9 | 9 | 3 | 3 | 4 | 235 | 6 | |
Pandemic Preparedness ($181.7m) | 23 | 5 | 50 | 22 | 31 | 21 | 6 | 6 | 113 | 16 | |
Implementation ($386.1m) | 19 | 0 | 8 | 13 | 24 | 10 | 3 | 1 | 57 | 62 | |
New Variants ($88.1m) | 109 | 3 | 35 | 21 | 3 | 19 | 39 | 0 | 9 | 0 |
Notes:
i. Research projects may be assigned with multiple cross-cutting themes and WHO priority areas
ii. Highlighted cells indicate the WHO Priority Area with the greatest number of projects for each cross-cutting theme (excluding projects that were not assigned a priority area, marked N/A).
iii. Funding figures available for 61.2% of projects included in the latest version of the tracker database as not all funders provided financial information.
iv. Definitions of cross-cutting themes-
◦ Capacity strengthening: Projects which involve a capacity strengthening component. Capacity strengthening at all levels- individual, institutional and national is included.
◦ Cohorts: Projects carried out in newly established cohorts or pivoted existing cohorts for COVID-19 research.
◦ Gender: Projects which incorporate a gendered lens in description of methods/ objectives and project outputs.
◦ Implementation: Grants for facilitating research administration.
◦ Indirect Health Impacts: Projects focusing on indirect health impacts of COVID-19, for example related to disruptions in healthcare services, neonatal, maternal and child health, non-communicable diseases, chronic disease conditions and mental health.
◦ Innovation: Projects involving novel inventions and interventions.
◦ Long COVID: Projects involving the long-term morbidity and enduring symptoms of COVID-19 beyond the initial infection.
◦ Modelling: Projects involving any form of modelling in the methodology.
◦ New Variants: Projects involving new variants of the coronavirus that cause COVID-19.
◦ Pandemic Preparedness: Projects with preparedness for future pandemics as an objective.
◦ Repurposed projects: Pre-COVID research grants (usually for MERS, SARS and other pathogens) where additional funding has been awarded for tailoring to COVID-19 research.